Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has announced the completion of the first dosing of the EP-0210 monoclonal antibody injection in a Phase I clinical trial for treating inflammatory bowel disease, indicating progress in its drug development pipeline [1][3]. Group 1: Drug Overview - EP-0210 monoclonal antibody injection is a humanized IgG1 monoclonal antibody targeting TNF-like ligand 1A (TL1A), aimed at treating inflammatory bowel disease by blocking TL1A-mediated pro-inflammatory signaling pathways [1][2]. - Preclinical studies have shown that EP-0210 has a clear mechanism of action and significant efficacy in various inflammatory bowel disease models, demonstrating better target activity and efficacy compared to the foreign competitor RVT-3101 [2]. Group 2: Clinical Trial Details - The Phase I clinical trial for EP-0210 received formal approval from the National Medical Products Administration in January 2026, with the trial focusing on safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult participants [3]. - As of the announcement date, the first dosing in the single-dose administration phase of the trial has been completed [3].

The pound also dipped against the euro, and for a short while, the dollar.Thanks for joining us. That’s all we have for today.Lloyd Harris at Premier Miton, which has just less than £10bn of assets under management, said a Rayner-led government posed a “threat to the gilt market”. Mr Harris warned of a more extreme reaction to Ms Rayner given “her championing of workers’ rights, increased public‑service investment, and expanded welfare support”. He said: “The implication is that she would appoint a Chancell ...

Company Overview - Merck & Co., Inc. has experienced a significant increase in its share price, rising nearly 50% over the past six months, indicating strong market performance [2]. Investment Potential - The company possesses a valuable portfolio of assets that is expected to generate strong shareholder returns, making it an attractive investment opportunity [2]. Research and Analysis - The Value Portfolio employs a fact-based research strategy to identify investments, which includes thorough analysis of 10Ks, analyst commentary, market reports, and investor presentations [3].

Company Overview - Merck & Co., Inc. (NYSE: MRK) has experienced a significant increase in its share price, rising nearly 50% over the past six months, indicating strong market performance [2]. Investment Potential - The company possesses a valuable portfolio of assets that is expected to generate strong shareholder returns, making it an attractive investment opportunity [2]. Research and Analysis - The Value Portfolio employs a fact-based research strategy to identify investments, which includes thorough analysis of 10Ks, analyst commentary, market reports, and investor presentations [3].

Core Viewpoint - Pfizer has been a disappointing stock in recent years, with a 38% decline over the past three years, primarily due to concerns about growth and upcoming patent expirations [1] Dividend Appeal - Pfizer offers a dividend yield of 6.3%, significantly higher than the S&P 500 average of 1.1%, making it an attractive option for income investors [2] - The sustainability of Pfizer's high dividend is questioned, especially since its diluted earnings per share for the year were $1.36, below the annual dividend payout of $1.72 [3][4] Earnings Forecast - For 2026, Pfizer projects adjusted per-share earnings to be between $2.80 and $3.00, suggesting potential safety for the dividend despite current concerns [5] Revenue and Growth Prospects - Pfizer's revenue declined by 2% in the past year, with modest expectations for improvement by 2026; however, the company has made investments and acquisitions that may enhance future growth [6] - The stock has seen a 6% increase over the past 12 months, indicating that it may be less vulnerable to further declines due to its lower valuation [7]

Core Insights - Iambic has entered a multi-year collaboration with Takeda Pharmaceutical to utilize its AI drug discovery models for advancing small molecule programs in oncology, gastrointestinal, and inflammation areas [1][4] - The collaboration could exceed $1.7 billion, including upfront payments, research costs, technology access payments, and success-based payments [3][4] - Iambic's AI-driven platform aims to significantly reduce drug discovery timelines from the traditional six years to less than two years [6][7] Company Overview - Iambic, founded in 2020 and based in San Diego, is a clinical-stage life-science and technology company focused on developing novel medicines through its AI-driven discovery platform [2] - The company will also receive royalties on net sales of any products resulting from the collaboration with Takeda [5] Industry Trends - The integration of AI technologies in drug discovery is becoming increasingly common, with predictions that timelines could be halved in the coming years [6] - The combination of AI predictions and automated laboratories is expected to accelerate the Design-Make-Test-Analyze cycle, enhancing program advancement [6][7]

Core Insights - Cancer has become the most lucrative area for the pharmaceutical industry, with global cancer drug sales exceeding $200 billion in 2024, making it the largest revenue category in biopharma [1] - Despite high sales, many profitable cancer drugs do not significantly extend patients' lives, with fewer than half of the 176 cancer drugs approved since 2000 showing clear improvement in overall survival [2][9] - The oncology market continues to grow due to regulatory changes that allow drugs to be approved based on surrogate endpoints like progression-free survival, which do not necessarily correlate with improved patient outcomes [7][8] Industry Trends - The immunotherapy revolution that began in 2011 has plateaued, with response rates for single-agent checkpoint inhibitors in melanoma ranging from 33% to 42%, and five-year survival rates peaking at 41% [4][5] - Combination therapies have increased response rates to around 60%, but they also come with severe toxicity rates exceeding 50%, impacting patients' quality of life [6] - The current system rewards speed and volume in drug approvals, leading to a disconnect between drug costs and actual patient benefits [10] Economic Pressures - Many leading checkpoint inhibitors are set to lose patent protection in the next two years, which may reduce financial incentives for further development [11] - The economic model of immunotherapy is facing challenges as extracting incremental benefits from aging assets becomes increasingly difficult [11] Emerging Solutions - New precision oncology approaches, such as Sona Nanotech's targeted hyperthermia therapy, aim to make tumors more recognizable to the immune system by releasing tumor antigens through localized treatment [13] - Sona's recent first-in-human study showed promising results, with eight out of ten melanoma patients responding to therapy and minimal toxicity observed [15] - The focus is shifting towards achieving maximum tumor response with minimal treatment-related toxicity, indicating a potential reset in oncology treatment paradigms [17]

Group 1 - The total number of shares composing the share capital as of January 31, 2026, is 83,814,526 [1] - The gross total of voting rights is 131,997,884, while the net total of voting rights is 130,585,862 [1][2] - There is a statutory clause that requires the declaration of threshold crossing, in addition to the legal thresholds [1] Group 2 - The gross total includes shares with double voting rights and treasury shares, while the net total excludes shares without voting rights [2]

Core Insights - Hims & Hers Health's stock dropped 25% after the company announced it would cease selling its compounded semaglutide weight-loss pill, just days after its launch, due to legal action from Novo Nordisk [1][1][1] - Novo Nordisk has filed a lawsuit against Hims & Hers, seeking to permanently ban the sale of unapproved compounded drugs that infringe on its patents and is pursuing damages [1][1][1] - Hims & Hers has faced significant stock depreciation, losing over 60% of its value in the past 12 months, while Novo Nordisk's shares have decreased by approximately 40% during the same period [1][1][1] Company Developments - Hims & Hers announced the discontinuation of its compounded weight-loss pill, which was marketed as having the same active ingredient as Novo Nordisk's Wegovy, following legal threats from Novo Nordisk [1][1][1] - The lawsuit from Novo Nordisk is described by Hims & Hers as a "blatant attack" on Americans who rely on compounded medications, indicating the company's intent to continue advocating for access to these treatments [1][1][1] Industry Context - The FDA has indicated plans to restrict the use of GLP-1 active ingredients in compounded weight-loss medications, specifically mentioning Hims & Hers in its statement [1][1][1] - Eli Lilly is anticipated to receive FDA approval for its own weight-loss pill later this year, which could further impact competition in the weight-loss drug market [1][1][1]

Core Viewpoint - AB Science has received FDA's Minor Use in Major Species (MUMS) designation for Masivet® to treat canine mast cell tumors, which is expected to facilitate its development and commercialization in the USA [1][3][4]. Company Overview - AB Science is a pharmaceutical company founded in 2001, specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [7][8]. - The company is headquartered in Paris, France, and is listed on Euronext Paris [8]. Product Information - Masivet® is a targeted therapy that inhibits juxtamembrane mutations of c-kit, the main driver of dog mast cell tumors [2]. - The MUMS designation provides seven years of exclusive marketing rights upon approval and eligibility for grants to support the approval process [3]. Market Potential - Masivet® is already registered and profitable in Europe but not yet in the USA; the MUMS status is seen as a significant encouragement for its development in the US market [4]. - AB Science aims to expand its animal health franchise, with expectations that EBITDA from this segment will help cover fixed costs and contribute to the company's financial stability [4]. Global Expansion Plans - The company is in discussions for distribution and commercialization agreements in various regions, including Europe (Norway, Denmark, Sweden, Finland, Lithuania), LATAM (Brazil, Argentina, Mexico), Asia (Japan, Taiwan), MENA regions, and South Africa [5]. - There is a global demand for Masivet, with positive feedback from pet owners and veterinarians regarding its safety and effectiveness [6].